Swine influenza, or “swine flu”, is a highly contagious acute respiratory disease of pigs, caused by one of several swine influenza A viruses. Morbidity tends to be high and mortality low (1-4%). The virus is spread among pigs by aerosols and direct and indirect contact, and asymptomatic carrier pigs exist. Outbreaks in pigs occur year round, with an increased incidence in the fall and winter in temperate zones. Many countries routinely vaccinate swine populations against swine influenza.
Swine influenza viruses are most commonly of the H1N1 subtype, but other subtypes are also circulating in pigs (e.g., H1N2, H3N1, H3N2). Pigs can also be infected with avian influenza viruses and human seasonal influenza viruses as well as swine influenza viruses. The H3N2 swine virus was thought to have been originally introduced into pigs by humans. Sometimes pigs can be infected with more than one virus type at a time, which can allow the genes from these viruses to mix. This can result in an influenza virus containing genes from a number of sources, called a “reassortant” virus. Although swine influenza viruses are normally species specific and only infect pigs, they do sometimes cross the species barrier to cause disease in humans.
At least 40% of current UK H1N1 deaths are among healthy adults.
HPA is receiving reports of fatal influenza cases from various sources (clinicians, laboratory reports and death certificates). These reports have been reconciled and verified with clinicians. These will not represent all influenza-related deaths.
Twenty-three of the 38 fatal cases with available information (61%) were in one of the CMO-defined clinical risk groups for vaccination.
The above data is from the latest report by the HPA and indicate that 39% of reported H1N1 fatalities had no broadly defined underlying condition. Although this level is slightly lower than the more than 50% reported last week, the reported cases will be heavily biased towards those with underlying conditions, who are the focus of almost every agency statement coming out of the UK. As noted above, the 38 fatal cases do not represent all H1N1 deaths. Many have not been confirmed and many will not be reported because of a lack of testing.
Virusolve+ from Amity has been tested and found to be effective against Parainfluenza, Avian Influenza & Influenza A (H3N2).
Swine Flu is a mutation of Influenza A. Hence we would expect Virusolve+ to be effective against H1N1.
Amity has geared up to respond to any emergency situation globally.
Amity’s Technical Director / CEO Ram Singh said ‘Amity has increased stock levels in the UK and our distributors around the world are carrying more stock to help decontaminate surfaces and the environment to prevent the spread of swine flu and help save lives in a potential pandemic situation.’